NCT05076071

Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors

Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors: A Multicenter Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Yizhuo Zhang · Academic / Other
• Sex: All
• Age: 0 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

Samples of 200 patients with pediatric malignant solid tumors will prospectively be collected. Selected samples are sufficient for next generation sequencing(NGS) and available for follow-up information. Multi-omics techniques such as DNA and RNA panel will be used to study driver genes for the development of malignant solid tumors in children, and to explore the pathogenic mechanism. The aim of this study is to explore new biomarkers for the diagnosis and treatment for childhood malignant solid tumors.

Detailed description

DNA and RNA extracted from tumor tissues and leukocytes will be analyzed by Onco PanScan/whole exon sequencing(Genetronhealth), and comprehensive gene mutation information such as single nucleotide variation, insertion deletion mutation, gene copy number variants and structure variants will be obtained. Through in-depth mining of genomic data generated by clinical tumor tissue detection, the differences among different subtypes of pediatric solid tumors in TCGA data will be compared with previous studies. Combined with clinical pathological and molecular subtyping results, auxiliary diagnosis was performed. Analyzing therapeutic targets and identifying pathogenic cancer-predisposing variants may provide molecular reference for children's malignant solid tumors.

Conditions

• Pediatric, Solid Tumors, NGS

Interventions

Type	Name	Description
GENETIC	NGS	Next Generation Sequencing

Timeline

• Start date: 2021-08-06
• Primary completion: 2023-07-06
• Completion: 2023-08-06
• First posted: 2021-10-13
• Last updated: 2021-10-13

Locations

1 site across 1 country: China